On Jun. 3, 2021, Resverlogix announced a partnership to support planned commercialization of apabetalone in the United States, Canada (where authorization had been granted to conduct clinical studies of apabetalone for COVID-19) and/or potentially expanding to additional global markets, as Emergency Use Authorization and/or a New Drug Application or equivalent was issued or approved.